McKesson Corporation (MCK)

McKesson's stock price has seen an increase over the past year and three months. Key events impacting MCK stock in the past six months include the divestiture of its Canada-based Rexall and Well.ca retail businesses, fiscal Q3 and Q4 2025 earnings reports, the acquisition of Core Ventures, and an Investor Day announcement.

Demand for McKesson's products and services can exhibit seasonality. The company has observed lower than anticipated volumes due to less demand for illness season products, particularly in the third fiscal quarter. Conversely, the fourth fiscal quarter is typically the busiest time of the year, driven by annual verifications and increased prescription transaction volumes. Demand for GLP-1 medications has significantly boosted revenue, but this growth can have variability from quarter to quarter. Additionally, the Medical-Surgical Solutions segment has faced softer demand, with reduced primary care demand as market conditions normalized after COVID-19.

McKesson Corp. is a global healthcare services company operating in the Healthcare sector, specifically within the Medical Distribution industry. The company's core business revolves around healthcare supply chain management, pharmaceutical distribution, and healthcare technology solutions. It distributes pharmaceutical drugs and healthcare-related products to various healthcare providers, offers medical supplies and equipment, provides healthcare technology solutions, and supports cancer care delivery through its US Oncology Network.

McKesson's primary geographic footprint is in North America, with significant operations in the United States and Canada. The company has been strategically exiting its European pharmaceutical wholesale and distribution businesses to focus capital on growth areas in the U.S., such as oncology and biopharma services. As of early 2023, McKesson was progressing on plans to exit the European region and had successfully exited 11 of the 12 countries it operated in, with Norway being the remaining country for divestiture.

Information specifically detailing events that have affected McKesson Corp.'s brand reputation in the past year is limited in the provided search results. However, it is important to note that McKesson has historically faced legal challenges, including a federal lawsuit for profiting from the opioid epidemic and a settlement related to allegations of misleading investors about profits from a generic drug pricing conspiracy. Ongoing legal and regulatory scrutiny is a general factor that can influence the company's reputation.

McKesson Corporation's ownership structure is a mix of institutional, insider, and retail/individual investors. Institutional shareholders hold a significant majority of the company's shares, with major institutional owners including Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Insiders own about 12.06% of the company, while retail investors hold approximately 1.78%.